Interestingly, L1EV α-synuclein/CD81 ratio exhibited an improved performance in differentiating individuals with either iRBD or PD from controls compared to the measurements of α-synuclein alone (Figure 5D). This evidence concerns the gene CD81 and Parkinson disease.